Voxvoganan: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -29% 1 23 Improvement, Studies, Patients Relative Risk Viral clearance -29% 1 23 RCTs -29% 1 23 Early -29% 1 23 Voxvoganan for COVID-19 c19early.org December 2025 Favorsvoxvoganan Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lütken (DB RCT) -29% 1.29 [0.20-8.28] viral load 11 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Early treatment -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk All studies -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk 1 voxvoganan COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Effect extraction pre-specified(most serious outcome) Favors voxvoganan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lütken (DB RCT) -29% 1.29 [0.20-8.28] viral load 11 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Early treatment -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk All studies -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk 1 voxvoganan COVID-19 viral clearance result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Favors voxvoganan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lütken (DB RCT) -29% 1.29 [0.20-8.28] viral load 11 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Early treatment -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk All studies -29% 1.29 [0.20-8.28] 11 (n) 12 (n) 29% higher risk 1 voxvoganan COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.8 Effect extraction pre-specified(most serious outcome) Favors voxvoganan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lütken (DB RCT) -29% 1.29 [0.20-8.28] viral load 11 (n) 12 (n) Improvement, RR [CI] Treatment Control Lütken (DB RCT) 6% 0.94 [0.08-11.4] viral load 11 (n) 12 (n) Lütken (DB RCT) -93% 1.93 [0.12-31.0] viral load 11 (n) 12 (n) Voxvoganan COVID-19 outcomes c19early.org December 2025 Favors voxvoganan Favors control